In practical terms, this means retatrutide users burn more calories at baseline than those on dual agonists alone
As GLP-1RAs continue to grow in popularity for managing type 2 diabetes and obesity, this pharmacovigilance study calls for increased awareness and careful perioperative planning among clinicians
This novel approach delivers unprecedented weight loss results, with Phase 2 trials showing an average of 24.2% body weight reduction at 48 weeks
Contact Us North Dallas Wellness Center www.drdavidfein.com (214) 696-3885 8230 Walnut Hill Lane, Suite 304 Dallas, Texas 75231
she is Board Certified in Obesity Medicine
As demand, accessibility and affordability increase, its likely the number of users will rise and its important for them to be informed